title: Antidepressant phenotype by inhibiting the phospholipase Cβ(1)--protein kinase Cγ pathway in the forced swim test.
abstract: Although great advances have recently been made in the study of signal transduction, the pathogenesis of affective disorders is still unknown. There is mounting evidence suggesting that elevated phosphoinositide-protein kinase C (PI-PKC) signal transduction pathway may be a pathophysiological feature of bipolar and major depressive disorders. The aim of the present study was to further investigated the phospholipase C-protein kinase C (PLC-PKC) cascade by evaluating the effect produced by an acute blockade of this intracellular pathway at PLC and PKC level. Adult male mice were administered with pharmacological inhibitors of PLC or PKC and then subjected to the forced swim test (FST), an animal model which emulates the behavioural despair paradigm of depression. In this study we also tested the hypothesis that it might be possible to selectively modulate depressive behaviour by inhibiting the expression of specific PLC and PKC isoforms by means of specific antisense oligonucleotides (aODNs). Administration of the PLC inhibitors neomycin and U73122 as well as of the PKC inhibitors calphostin C and chelerytrine dose-dependently reduced the immobility time in the FST producing an antidepressant-like behaviour. Selective knockdown of the PLCβ(1) and PKCγ isoforms also induced an antidepressant phenotype. Conversely, the inhibition of the expression of PLCβ(3) was unable to modify the immobility time values. The PLC and PKC modulators used, at the highest effective doses, altered neither locomotor activity nor motor coordination. We demonstrate that selective blockade of PLCβ(1)-PKCγ signalling pathway produces an antidepressant-like phenotype in mice.
authors.affiliation: Department of Preclinical and Clinical Pharmacology, Viale G. Pieraccini 6, 50139 Florence, Italy. nicoletta.galeotti@unifi.it
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Galeotti
authors.forename: Carla
authors.initials: C
authors.lastname: Ghelardini
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D053119:Benzophenanthridines / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004963:Estrenes / Q000494:pharmacology; D055785:Gene Knockdown Techniques / Q000379:methods; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000494:pharmacology; D009355:Neomycin / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010641:Phenotype; D054799:Phospholipase C beta / Q000037:antagonists & inhibitors* / Q000235:genetics; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000235:genetics; D011597:Psychomotor Performance / Q000187:drug effects; D011760:Pyrrolidinones / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D013550:Swimming
chemical_list: D000928:Antidepressive Agents; D053119:Benzophenanthridines; D004791:Enzyme Inhibitors; D004963:Estrenes; D009281:Naphthalenes; D016376:Oligonucleotides, Antisense; D011760:Pyrrolidinones; C061465:calphostin complex; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; C016299:chelerythrine; C087857:protein kinase C gamma; D011493:Protein Kinase C; D054799:Phospholipase C beta; D009355:Neomycin